Comparative Infection Risk with TNF Monoclonal Antibodies Versus Etanercept in Axial Spondyloarthritis: A Real-World Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1676; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Adults ≥18 with ankylosing spondylitis or non-radiographic axial spondyloarthritis initiating TNF monoclonal antibodies (adalimumab, infliximab, golimumab, or certolizumab) (n=24,450) were compared with new users of etanercept (n=7,736), excluding prior exposure to the comparator class within one year before index. In this large real-world cohort of patients with axial spondyloarthritis, TNF monoclonal antibodies were not associated with a significantly increased risk of sepsis or herpes zoster compared with etanercept. Absolute event rates were low, and differences between TNF inhibitor classes were small and not statistically significant, supporting similar infection safety profiles in routine clinical practice."
Clinical • Real-world • Real-world evidence • Ankylosing Spondylitis • Axial Spondyloarthritis • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • Seronegative Spondyloarthropathies • Spondylarthritis • Varicella Zoster
|
|
Bsher Almaalouli1; Harini Reddy Choula1; Madhuri Banoth2; Maya Khasho1; Sameh Madanieh3; alaa Alhalabi4; Aseed Mestarihi1; Miguel Rodriguez5
|